special story
KEY FACTS:
• India which today occupies only 3% of the biopharmaceuticals
global market aims to reach 5% by 2022.
• The National Biopharma Mission will create an ecosystem for
innovative indigenous product development by researchers,
start-ups and SMEs and make Indian biotech industry globally
competitive.
• It will make the sector globally competitive over the next 10-15
years. It will transform the health standards of India’s population
through affordable product development.
concerned Ministries: Dr Soumya
Swaminathan, DG- ICMR; Dr J P
Prakash; Secretary Department
of Pharmaceuticals, Dr G N Singh
DCGI and DBT officials.
The program launch occasion was
also graced by the presence of
eminent scientists from academia
and representatives from the Indian
industry. It promises to boost
the growth curve for domestic
biopharma in India by accelerating
the translation of research
concepts into viable products,
enabling sustainable networks for
collaboration between industry
and academia, and supporting
entrepreneurial ecosystem amongst
46
BioVoiceNews | July 2017
many others.
The Mission is much in sync
with the National Biotechnology
Development Strategy 2015-2020
announced earlier by the DBT. It
lays emphasis on making India
ready to meet the challenge of
achieving US $100 billion biotech
industry by 2025. The key focus
areas of the program would aid in
preparing India’s technological and
product development capabilities
in the biopharmaceutical sector to
a level that it is globally competitive
over the next 10-15 years and will
transform the health standards
of India’s population through
affordable product development.